Phenotypic and genotypic characterisation of thymine auxotrophy in *Escherichia coli* isolated from a patient with recurrent bloodstream infection

Aleksandra Jakovljev¹, Jan Egil Afset¹,², Kjersti Haugum¹,², Harald Otto Steinum³, Torunn Gresdal Rønning¹,², Ørjan Samuelsen⁴,⁵, Christina Gabrielsen Ås¹,²*

¹ Department of Medical Microbiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, ² Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, ³ Department of Infectious Diseases, Clinic of Internal Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, ⁴ Department of Microbiology and Infection Control, Norwegian National Advisory Unit on Detection of Antimicrobial Resistance, University Hospital of North Norway, Tromsø, Norway, ⁵ Department of Pharmacy, UiT The Arctic University of Norway, Tromsø, Norway

* christina.gabrielsen@stolav.no

Abstract

Introduction
Thymine auxotropic in vitro mutants of *Escherichia coli* were first reported in the mid-20th century. Later, thymine-dependent clinical strains of *E. coli* as well as other Enterobacteriales, *Enterococcus faecalis* and *Staphylococcus aureus* have been recognized as the cause of persistent and recurrent infections.

Objectives
The aim of this study was to characterize the phenotype and investigate the molecular basis of thymine auxotrophy in ten *E. coli* isolates obtained at different time points from a patient with recurrent bloodstream infection (BSI) due to a chronic aortic graft infection treated with Trimethoprim/sulfamethoxazole (TMP-SMX).

Methods
Clinical data was obtained from hospital records. Growth characterization and antimicrobial susceptibility testing to TMP-SMX was performed on M9 agar and in MH broth with different thymine concentrations (0.5, 2, 5, 10 and 20 μg/mL), on Mueller-Hinton (MH) and blood agar. Whole genome sequencing (WGS) was performed on all *E. coli* isolates.

Results
*E. coli* were isolated from ten consecutive BSI episodes from a patient with chronic aortic graft infection. Six of these isolates were resistant to TMP-SMX when assayed on blood agar. Growth experiments with added thymine confirmed that these isolates were thymine-dependent (*thy*), and revealed growth defects (slower growth rate and smaller colony size).
in these isolates relative to thy+ isolates (n = 4). WGS indicated that all isolates were of the same clonal lineage of sequence type 7358. Genomic analysis revealed a G172C substitution in thyA in all TMP-SMX resistant isolates, while mutations affecting genes involved in the deoxyribose salvage pathway (deoB and deoC) were identified in eight isolates.

Conclusion
This case highlights the risk of resistance development to TMP-SMX, especially for long-term treatment, and the possible pitfalls in detection of growth-deficient subpopulations from chronic infections, which could lead to treatment failure.

Introduction
Trimethoprim (TMP) and sulfamethoxazole (SMX) are synthetic antimicrobial agents that target bacterial folate synthesis and have been used in combination since 1968 [1]. TMP-SMX has a wide antibacterial spectrum covering Enterobacterales, including Escherichia coli, Salmonella spp. and Shigella spp., Haemophilus influenzae as well as Staphylococcus aureus, and is commonly used as first-line treatment for urinary tract infections (UTIs) [1].

The frequency of TMP-SMX resistance among clinical strains varies greatly, depending on the bacterial species, clinical sample type and geographical region. For E. coli, resistance rates of 15–65% in urine samples have been reported from different parts of the world, generally with higher rates in developing countries [2]. In Norway, the resistance rates for clinical E. coli strains were 23.1% in blood cultures and 21.3% in urine specimens in 2020 [3]. Co-resistance to TMP-SMX is also frequent among extended-spectrum-β-lactama se (ESBL)-producing and carbapenemase-producing Enterobacterales [4].

The molecular mechanism of TMP and SMX action is based on inhibition of the synthesis and conversion of tetrahydrofolate (THF), an essential cofactor involved in nucleotide synthesis, by acting as competitive inhibitors of dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) accordingly [5]. Resistance to TMP and SMX is mediated by different mechanisms. This includes horizontally acquired modified target enzymes, changes in regulation of target enzymes, mutation of target enzymes and changes in permeability and efflux [1, 2, 6].

One previously described mechanism of resistance to TMP-SMX is based on mutations causing loss or reduced function of the enzyme thymidylate synthetase, encoded by thyA, which is involved in thymidine synthesis and requires THF as a cofactor [7–9]. This blocks thymidine synthesis and results in auxotrophs which cannot survive without an external supply of thymine. Thymine-dependent (thy-) in vitro E. coli mutants were first described in the mid-20th century [10]. There has since been reports of thy- clinical strains of E. coli as well as other Enterobacterales, Enterococcus faecalis and S. aureus [7, 11]. Such auxotrophs have often been identified as small colony variants (SCVs) isolated from patients with persistent infections on long-term antimicrobial treatment [12, 13]. In addition to their small colony size, SCVs are often characterized by slow growth as well as altered phenotypic and biochemical traits, and importantly, often display lowered susceptibility to antibiotics [14]. The in vivo development of thymine auxotrophic SCVs of S. aureus has been widely described due to their role in persistent and recurrent infections [15, 16], while this phenomenon is less reported for E. coli. A few recent studies have however investigated the phenotypic and genetic basis of thymine-dependent ESBL-producing clinical E. coli strains from patients with UTIs [17, 18].
In this study, we characterize the phenotype and investigate the molecular basis of thymine auxotrophy in ten ESBL-producing *E. coli* isolates from a patient with recurrent bloodstream infection (BSI) due to a chronic aortic graft infection treated with TMP-SMX.

**Case presentation**

A 79-year old Caucasian male was admitted to St. Olavs University Hospital Trondheim, Norway, in December 2011 after a six month history with intermittent fever and unspecific symptoms (Table 1). He had an abdominal aortic graft inserted five years previously due to a progressively dilating abdominal aortic aneurysm. The postoperative course had been protracted, with pancreatitis as well as renal failure due to an obliterated left renal artery. In addition, an aortoduodenal fistula had been suspected based on CT imaging, but this had been considered inoperable. Blood cultures taken during admission yielded mixed faecal flora suggesting a gastrointestinal focus, and an infected aortic graft was suspected as the focus of infection. The patient subsequently recovered and was discharged on long-term antimicrobial treatment (Table 1).

During the next four years the patient experienced several new infection episodes, including an episode of L5 spondylodiscitis with *Candida albicans*, as well as repeated bloodstream infections with *E. coli* and/or *Enterococcus faecium* and *Saccharomyces cerevisiae*. After one of the BSI episodes, a fistula from colon sigmoideum to the bladder wall was detected and closed surgically. Antimicrobial treatment was instituted and adjusted according to microbial identification and susceptibility testing for each infection episode (Fig 1). The patient also experienced repeated episodes of melena, probably due to the aortoduodenal fistula, which was treated with blood transfusions. However, the complex situation with repeated infection episodes led to progressive deterioration and the patient died in August 2015.

**Methods**

**Bacterial isolates and clinical data**

Ten ESBL-producing *E. coli* isolates from recurrent BSI episodes (one isolate per episode) collected from June 2014 to July 2015 from a patient with chronic aortic graft infection were included in this study. Clinical data including antimicrobial treatment were collected from hospital records.

| Year | Month  | Clinic                  | Specimen type          | Findings                  | Treatment                                                                 |
|------|--------|-------------------------|------------------------|---------------------------|---------------------------------------------------------------------------|
| 2011 | December | Pancreatitis, renal failure | Blood culture          | Mixed fecal flora          | Ciprofloxacin, amoxicillin, metronidazole                                  |
| 2013 | July   | Osteomyelitis L5         | Tissue biopsy L5       | *C. albicans*              | Ciprofloxacin, amoxicillin, metronidazole, fluconazole                    |
| 2014 | June   | BSI                     | Blood culture          | *E. coli*                 | Meropenem, TMP-SMX                                                        |
| 2014 | August | BSI                     | Blood culture          | *E. coli*                 | Meropenem, TMP-SMX                                                        |
| 2014 | September | BSI                   | Blood culture          | *E. coli*                 | Ciprofloxacin, linezolid                                                  |
| 2014 | October | BSI                     | Blood culture          | *E. faecium*              | Ciprofloxacin, linezolid                                                  |
| 2014 | November | BSI                   | Blood culture          | *E. coli, S. cerevisiae*  | TMP-SMX, meropenem, voriconazole, ertapenem                                |
| 2014 | December | BSI                    | Blood culture          | *E. coli*                 | Meropenem                                                                |
| 2015 | February I | BSI                   | Blood culture          | *E. coli, E. faecium*     | Meropenem, linezolid                                                      |
| 2015 | February II | BSI                  | Blood culture          | *E. coli, E. faecium and S. cerevisiae* | Meropenem, linezolid, micafungin                                       |
| 2015 | May I  | BSI                     | Blood culture          | *E. coli*                 | Tigecycline, fluconazole                                                  |
| 2015 | May II | BSI                     | Blood culture          | *E. coli*                 | Tigecycline, fluconazole                                                  |
| 2015 | July   | BSI                     | Blood culture          | *E. coli*                 | Tigecycline, fluconazole                                                  |

https://doi.org/10.1371/journal.pone.0270256.t001
Antimicrobial susceptibility testing

Bacterial isolates from positive blood cultures were initially grown on blood- and MacConkey agar, while direct antimicrobial susceptibility testing (AST) from blood culture bottles was performed on MH-agar using the disk diffusion method and interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints [19]. In cases where no growth was observed on MH-agar, 5–7 colonies from blood agar were collected for alternative AST on blood agar, with *E. coli* CCUG 17620 as a susceptible control strain. All *E. coli* isolates except from the first and the sixth BSI episodes were originally sent to the Norwegian National Advisory Unit on Detection of Antimicrobial Resistance (K-res) for confirmation of ESBL. Repeated AST of TMP-SMX for all isolates was subsequently performed with MIC Test Strip (Liofilchem) on MH-agar, blood agar and M9 agar medium added thymine (0.5, 2, 5 and 20 μg/mL).

Growth assays

Growth characteristics of the *E. coli* isolates were assayed both on solid and in liquid M9 minimal medium with 0.4% glucose supplemented with thymine. *E. coli* CCUG 17620 was used as a positive control. The *E. coli* isolates were first incubated in 5% CO₂ at 35°C for 18–20 hours on blood agar, before resuspension to 0.5 McFarland. The suspension was floated on M9 agar supplemented with 0, 0.5, 2, 5 and 20 μg/mL thymine and plates examined for growth after 24, 48, 72 and 96 hours incubation. The classical auxotroph test was performed by placing discs soaked for 2–3 minutes in liquid MH-broth supplemented with 0, 0.5, 2, 5, 10, 20 and 40 μg/mL thymine on M9 agar plates floated with bacterial culture. Plates were examined every 24 hours for 7 days. For growth assays in liquid medium, 200 μl suspension (0.5 McFarland) was added to 200 μl liquid MH medium to a total concentration of 0, 0.5, 2, 5, 10 and 20 μg/mL thymine. Plates were incubated at 37°C with continuous high-amplitude normal speed shaking and assayed by measuring optical density at 600 nm at 1 hour intervals for a total of 12 hours using a BioScreen C instrument (Oy Growth Curves Ab Ltd). Growth curves of three technical replicates and three biological replicate experiments for each isolate were analysed with logistic regression and replicates test using Prism GraphPad software.

Whole genome sequencing and bioinformatic analysis

Genomic DNA was extracted using the MagAttract DNA Mini M48 Kit and BioRobot M48 instrument (Qiagen). The isolates were whole genome sequenced (WGS) using Nextera XT sample prep kit and MiSeq platform (Illumina) with 300-bp paired-end reads (MiSeq Reagent Kit).
Kit v3). Raw data were quality controlled, trimmed/filtered and de novo assembled (Shovill v.1.0.9), and the assembled genomes annotated and typed (E. coli multi-locus sequence typing (MLST) Achtman scheme) with the Nullarbor pipeline version 2.0 using default settings [20, 21]. Resistance genes were identified using the NCBI National Database of Antibiotic Resistant Organisms [22]. Core genome phylogeny and distance estimation was performed using Roary [23], FastTree with the GTR model [24] and Molecular Evolutionary Genetics Analysis (MEGA) [25]. These analyses included 48 publically available reference genomes of different E. coli phylogroups and sequence types (ST), including ST7358 (n = 6) and ST405 (n = 8). Genomic analyses were directed towards mutations previously described in thymine auxotrophy and/or genes involved in thymidine de novo and salvage pathways. WGS assemblies are available from BioProject PRJNA785617.

Ethics
Informed verbal consent was obtained from the patient during hospitalization. The study was approved by the Regional Committee for Medical and Health Research Ethics, Mid-Norway (REK 2016/1367).

Results
Isolation of TMP-SMX resistant E. coli from a patient with recurrent BSI
ESBL-producing E. coli were isolated from ten consecutive BSI episodes over 14 months (June 2014-July 2015) from a patient with chronic aortic graft infection (Table 1 and Fig 1). The E. coli isolate from the first BSI episode grew on MH-agar and was susceptible to TMP-SMX. After introduction of TMP-SMX prophylaxis, E. coli isolates that did not grow on MH-agar and were resistant to TMP-SMX were isolated from two succeeding BSI episodes. Cessation of prophylaxis was followed by isolation of a TMP-SMX susceptible isolate during the fourth BSI episode. On this occasion, due to detection of multi-resistant ESBL-producing E. coli, parenteral therapy with TMP-SMX was given for two weeks. After the fifth BSI episode with TMP-SMX resistant E. coli, therapy was changed to meropenem. TMP-SMX resistant E. coli were isolated from the three next BSI episodes, despite TMP-SMX not being used for further treatment. From the ninth and tenth BSI episodes TMP-SMX susceptible E. coli were isolated. All isolates were non-hemolytic on blood agar.

Growth assays and antimicrobial susceptibility testing of E. coli BSI isolates
Suspecting that the lack of growth on MH medium was due to its low thymine content, growth experiments were subsequently performed on/in M9 medium with and without added thymine. The results revealed that all the TMP-SMX susceptible E. coli isolates grew both with and without added thymine after 12/24 hours incubation in liquid and on solid medium accordingly (Table 2 and Fig 2). However, neither of the TMP-SMX resistant E. coli isolates grew on/in M9 medium without thymine, indicating that these isolates were thymine auxotrophs (thy-). All isolates grew on/in M9 medium with added thymine, even at the lowest thymine concentration tested, but with variable growth rates and colony morphologies. Whereas TMP-SMX susceptible isolates displayed normal colony size after 18 hours of incubation, colonies of TMP-SMX resistant isolates were clearly smaller, in some cases barely visible, even after prolonged incubation (96 hours). In the classical auxotroph test, TMP-SMZ resistant isolates did not grow at low concentrations of thymine, but gradually better at the highest concentrations (Fig 3). The TMP-SMX resistant isolates also displayed slightly reduced growth rate (k) and/or maximum cell density (Y_max) in liquid M9 medium with 0.5 μg/mL thymine (Fig 2 and
Antimicrobial susceptibility testing was subsequently performed on M9 agar medium with added thymine, which confirmed the previous results from MH-agar and blood agar (Table 2). Four of the isolates were susceptible to TMP-SMX, having MICs ranging from 0.032–1 μg/mL on all media tested, whereas six isolates were resistant having MIC values of >32 μg/mL. Even though reversion of thymine auxotrophs to the wild-type phenotype is a well-known phenomenon, this was not observed in this study, even after prolonged incubation. However, serial subcultivations were not performed, as characterization of reversion was beyond the scope of this study.

Clonality and identification of mutations associated with TMP-SMX resistance and thymine auxotrophy

WGS was performed to determine whether the E. coli isolates were clonal. Results from in silico MLST showed that all isolates were ST7358. This sequence type belongs to clonal complex 405, which also includes the well-known multidrug resistant uropathogenic E. coli ST405 lineage. Core genome phylogeny (S1 Fig) confirmed that the isolates were clonal, and core genome distances between isolates ranged from 0–16 SNPs, except the isolate from the second BSI episode, which differed by 70–83 SNPs. Resistance gene prediction revealed that all isolates shared nine antibiotic resistance-related genes (Table 3) including the sul1 gene, which is associated with sulfonamide resistance. The isolate from the first BSI episode additionally carried the tetB gene. Six isolates carried the ESBL gene blaCTX-M-55 (blaCTX-M-1 group), while in four isolates a single amino acid variant (N109S) of blaCTX-M-55 was identified. No acquired resistance genes related to trimethoprim resistance were identified. However, there were identified mutations in three genes involved in the pathways for thymidylate synthesis when compared to the initial TMP-SMX susceptible E. coli isolate (Fig 1). The six TMP-SMX resistant isolates shared a mutation in the thymidylate synthase gene (thyA), specifically a previously described G172C substitution in thyA causing a Glu-58 to Gln-58 change in thymidylate synthase (3). Furthermore, mutations affecting genes involved in the deoxyribose salvage pathway were identified in eight isolates (three susceptible and five resistant). These mutations include a C801A substitution causing a premature stop codon in deoB in one susceptible isolate and a 515 bp deletion in the start of deoC in seven isolates (two susceptible and five resistant). Mutations in these
Fig 2. Growth (OD$_{600}$) of *E. coli* BSI isolates at 37˚C in liquid M9 medium with added thymine.

https://doi.org/10.1371/journal.pone.0270256.g002
genes can inhibit the catabolism of deoxyribose-1-phosphate, which is of critical importance for thymine uptake and utilization (4–7). For all other genes analysed, including, deoA, deoR, deoD, tmk/ycfG, ndk, tdk, cdd, add, dgt, yjjG, nupG and nupC, no mutations were identified.
Table 3. Resistance genes identified in the 10 *E. coli* isolates from recurrent BSI episodes.

| BSI episode | Isolate     | No. of genes | *aac(6')-Ib-D181Y* (aminoglycosides) | *armA* (aminoglycosides) | *arr-3* (rifamycins) | *blaCTX-M-55* (beta-lactams) | *blaOXA-1* (beta-lactams) | *catB3* (phenolics) | *mph(E)* (macrolides) | *msr(E)* (macrolides) | *sul1* (sulfonamides) | *tet(B)* (tetracyclines) |
|-------------|-------------|--------------|--------------------------------------|--------------------------|----------------------|-----------------------------|--------------------------|------------------|----------------------|----------------------|----------------------|------------------------|
| 1           | SO-ECO14-1  | 10           | ✔                                    | ✔                        | ✔                    | ✔                           | ✔                        | ✔                | ✔                    | ✔                    | ✔                    | ✔                      |
| 2           | SO-ECO14-2  | 9            | ✔                                    | ✔                        | ✔                    | ✔                           | ✔                        | ✔                | ✔                    | ✔                    | ✔                    | ✔                      |
| 3           | SO-ECO14-3  | 9            | ✔                                    | ✔                        | ✔                    | ✔                           | ✔                        | ✔                | ✔                    | ✔                    | ✔                    | ✔                      |
| 4           | SO-ECO14-4  | 9            | ✔                                    | ✔                        | ✔                    | ✔                           | ✔                        | ✔                | ✔                    | ✔                    | ✔                    | ✔                      |
| 5           | SO-ECO14-5  | 9            | ✔                                    | ✔                        | ✔                    | ✔                           | ✔                        | ✔                | ✔                    | ✔                    | ✔                    | ✔                      |
| 6           | SO-ECO15-1  | 9            | ✔                                    | ✔                        | ✔                    | ✔                           | ✔                        | ✔                | ✔                    | ✔                    | ✔                    | ✔                      |
| 7           | SO-ECO15-2  | 9            | ✔                                    | ✔                        | ✔                    | ✔                           | ✔                        | ✔                | ✔                    | ✔                    | ✔                    | ✔                      |
| 8           | SO-ECO15-3  | 9            | ✔                                    | ✔                        | ✔                    | ✔                           | ✔                        | ✔                | ✔                    | ✔                    | ✔                    | ✔                      |
| 9           | SO-ECO15-4  | 9            | ✔                                    | ✔                        | ✔                    | ✔                           | ✔                        | ✔                | ✔                    | ✔                    | ✔                    | ✔                      |
| 10          | SO-ECO15-5  | 9            | ✔                                    | ✔                        | ✔                    | ✔                           | ✔                        | ✔                | ✔                    | ✔                    | ✔                    | ✔                      |

1 Note: Single amino acid variant (N109S) of CTX-M-55 was identified.

https://doi.org/10.1371/journal.pone.0270256.t003
Discussion

In this study we have characterized the phenotype and investigated the genetic basis for thymine auxotrophy and corresponding resistance against TMP-SMX in ESBL-producing *E. coli* isolates from blood cultures from a patient exposed to prolonged TMP-SMX treatment due to a chronic implant device infection. The isolation of alternating TMP-SMX resistant and susceptible isolates correlated with the initiation and termination of treatment during the investigated period (Fig 1). These results suggest that resistance to TMP-SMX was selected for *in vivo*. Resistant isolates were detected for a significantly longer period after cessation of TMP-SMX therapy in November 2014 than after termination of TMP-SMX prophylaxis in September 2014. It is possible that treatment with higher concentrations of TMP-SMX during the parenteral therapy enhanced by repeated exposure to the antimicrobials has exerted a strong selective pressure, thus providing a fitness advantage for the TMP-SMX resistant mutants.

Results from WGS indicated that all isolates belonged to the same clonal lineage. The recurrent BSI episodes are thus more likely to represent a relapsing infection caused by a heterogeneous population of isolates originating from a single clone, rather than successive reinfections with new *E. coli* strains. Given the case presentation of this patient, it can be speculated that a weakened innate immune response combined with microbial contamination of the inserted abdominal aortic graft has led to establishment of a chronic biofilm-associated infection [26].

Growth experiments with added thymine confirmed that the TMP-SMX resistant isolates were thymine-dependent, and revealed growth defects (slower growth rate and smaller colony size) in these isolates relative to the *thy*+ *E. coli* isolates on MH and M9 medium. Genomic analyses revealed mutations in the gene encoding thymidylate synthase (*thyA*) and in genes related to the deoxyribose salvage pathway, that were likely to be the cause of the *thy* and TMP-SMX resistant phenotype. The G172C *thyA* mutation was found in all TMP-SMX resistant isolates, indicating that this was the primary resistance determinant. This substitution has previously been demonstrated to decrease catalytic activity and ligand binding in *E. coli* thymidylate synthase, thus inhibiting the sole *de novo* pathway for thymidine [27]. Mutations/deletions in *deoB* and *deoC* were identified in TMP-SMX resistant as well as susceptible isolates (Fig 1). These are generally considered as secondary mutations, providing adaptation of *thyA* auxotrophs to a lower thymine requirement (2–5 μg/mL) (4). Interestingly, all our TMP-SMX resistant isolates did eventually grow on the lowest thymine concentration tested (0.5 μg/mL). This normally requires additional mutations in *deoR* (not observed in this study) described in low thymine-requiring strains growing on 0.2–0.5 μg/mL thymine [28]. The last two *E. coli* TMP-SMX susceptible *thy*+ isolates in our study have maintained *deoC* mutations, despite the loss of the *thyA* mutation, pointing to a possible selective advantage of this mutation in absence of TMP-SMX treatment/prophylaxis.

Whether TMP-SMX resistance was selected for on several occasions or there was a mixed population of resistant and susceptible isolates present during the whole period is uncertain. The characteristics of *thy*+ and *thy*− colonies on blood agar were undistinguishable and detection of TMP-SMX susceptible *thy*+ isolates could not preclude the presence of a *thy*− subpopulation. It is therefore possible that a heterogenic population including both *thy*+ and *thy*− *E. coli* isolates were present in the original blood cultures in these cases. This may have significance when TMP-SMX therapy is considered for long-term treatment of chronic infections [29]. In the case of our patient, resistance against TMP-SMX was detected both after short and prolonged courses of treatment and therefore the choice of TMP-SMX therapy should be
taken with cautiousness in patients with Enterobacterales BSI when transition from intravenous to peroral therapy is considered [30].

This case highlights the risk of resistance development to TMP-SMX, especially for long-term treatment, and the possible pitfalls in detection of growth-deficient and/or resistant subpopulations from chronic infections, which could lead to treatment failure. Our findings are thus of importance for the safe and effective use of TMP-SMX in clinical settings.

Supporting information
S1 Fig. Midpoint-rooted core genome phylogeny of E. coli clinical isolates and 48 publicly available reference genomes of different E. coli phylorgups and sequence types. The main sequence types are coloured according to the legend.  
(PDF)

S1 Table. Results from disk diffusion AST and ESBL PCR of E. coli BSI isolates. AMP, ampicillin; CTX, cefotaxime; CAZ, ceftazidime; CEF, cefuroxime; CIP, ciprofloxacin; GN, gentamicin; MER, meropenem; PIP-TAZ, piperacillin-tazobactam; TMP-SMX, trimetoprim-sulfamethoxazole; MIC, Strip Gradient test; TIG, tigecycline; “-”, not investigated.  
(DOCX)

S2 Table. Results from linear regression of growth of BSI isolates in liquid M9 minimal medium with 0.4% glucose supplemented with thymine.  
(XLSX)

Acknowledgments
Part of this work was presented at the 27th ECCMID 2017, 22–25 April, Vienna, Austria (Poster presentation): Jakovljev A, Afset JE, Haugum K, Steinum H, Rønning TR, Samuelsen Ø, Gabrielsen C. Genetic basis of growth characteristics and trimethoprim-sulfamethoxazole susceptibility of thymine-dependent and thymine independent serial blood culture isolates of Escherichia coli.

We thank to Department of Medical Microbiology, St. Olavs University Hospital in Trondheim, especially to Marit Gaustad for preparation of laboratory reagents and Alexander Husby for technical assistance, and Marte Singsås Dragset and Anne Marstad, Department of Clinical and Molecular medicine, NTNU for access to and technical advice on use of the BioScreen C instrument.

Author Contributions
Conceptualization: Aleksandra Jakovljev, Jan Egil Afset, Kjersti Haugum, Harald Otto Steinum, Torunn Gresdal Rønning, Christina Gabrielsen Ås.

Data curation: Aleksandra Jakovljev, Jan Egil Afset, Kjersti Haugum, Harald Otto Steinum, Torunn Gresdal Rønning, Christina Gabrielsen Ås.

Formal analysis: Aleksandra Jakovljev, Jan Egil Afset, Kjersti Haugum, Torunn Gresdal Rønning, Ørjan Samuelsen, Christina Gabrielsen Ås.

Investigation: Aleksandra Jakovljev, Jan Egil Afset, Kjersti Haugum, Harald Otto Steinum, Torunn Gresdal Rønning, Ørjan Samuelsen, Christina Gabrielsen Ås.

Methodology: Aleksandra Jakovljev, Jan Egil Afset, Kjersti Haugum, Torunn Gresdal Rønning, Ørjan Samuelsen, Christina Gabrielsen Ås.
Validation: Aleksandra Jakovljev, Jan Egil Afset, Kjersti Haugum, Torunn Gresdal Rønning, Ørjan Samuelsen, Christina Gabrielsen Ås.

Visualization: Christina Gabrielsen Ås.

Writing – original draft: Aleksandra Jakovljev, Jan Egil Afset, Kjersti Haugum, Christina Gabrielsen Ås.

Writing – review & editing: Aleksandra Jakovljev, Jan Egil Afset, Kjersti Haugum, Harald Otto Steinum, Torunn Gresdal Rønning, Ørjan Samuelsen, Christina Gabrielsen Ås.

References

1. Lewis James S. II and Bush Karen. Antibacterial Agents. In: Carroll KC, Phaller MA, Landry ML, McAdam AJ, Patel R, Richter S. Manual of Clinical Microbiology, 12th edition, 2019, p. 1201–41

2. Mortazavi-Tabatabaei SAR, Ghaderkhan i J, Nazari A, Sayehmiri K, Sayehmiri F, Pakzad I. Pattern of Antibacterial Resistance in Urinary Tract Infections: A Systematic Review and Meta-analysis. Int J Prev Med 2019; 10:169. https://doi.org/10.4103/ijpvm.IJPVM_419_17 PMID: 32133087

3. NORM/NORM-VET 2020. Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway. Tromsø / Oslo 2021. ISSN:1502-2307 (print) / 1890–9965 (electronic).pp.91-6

4. Livermore DM, Mushtaq S, Warner M, Woodford N. Comparative in vitro activity of sulfamethoxazole/trimethoprim and other agents against multiresistant Gram-negative bacteria. J Antimicrob Chemother 2014; 69: 1050–6 https://doi.org/10.1093/jac/dkt455 PMID: 24257317

5. Hitchings GH. Mechanism of action of trimethoprim-sulfamethoxazole. I. J Infect Dis. 1973; 128: Suppl:433–6 p.

6. Huovinen P, Sundstrom L, Swedberg G, Skold O. Trimethoprim and sulfonamide resistance. Antimicrob Agents Chemoth. 1995; 39(2):279–89. https://doi.org/10.1128/AAC.39.2.279 PMID: 7726483

7. King CH, Shlaes DM, Dui MJ. Infection Caused by Thymidine-Required, Trimethoprim Resistant Bacteria. J Clin Microbiol, July 1983, p. 79–83 https://doi.org/10.1128/jcm.18.7.83.1983 PMID: 6604070

8. Kriegeskorte A, Block D, Drescher M, Windmüller N, Mellmann A, Baum C et al. 2014. Inactivation of thyA in Staphylococcus aureus attenuates virulence and has a strong impact on metabolism and virulence gene expression. mBio 5(4):e01447–14. https://doi.org/10.1128/mBio.01447-14 PMID: 25073642

9. Besier S, Zander J, Kahl BC, Kraiczy P, Brade V, Wichelhaus TA. The Thymidine-Dependent Small-Colony- Variant Phenotype is Associated with Hypermutability and Antibiotic Resistance in Clinical Staphylococcus aureus Isolates. Antimicrob Agents Chemoth, June 2008, p. 2183–9 https://doi.org/10.1128/AAC.01395-07 PMID: 18378706

10. O’Donovan GA, Neuhard J. Pyrimidine metabolism in microorganisms. Bacteriol Rev. 1970; 34(3):278–343. https://doi.org/10.1128/bxr.34.3.278-343.1970 PMID: 4919542

11. Maskell R, Okubadejo OA, Payne RH, Pead L. Human infections with thymine-requiring bacteria. J Med Microbiol. 1983; 11(1):33–45. https://doi.org/10.1099/00222615-11-1-33 PMID: 621731

12. Proctor RA, von Elff C, Kahl BC, Becker K, McNamara P, Herrmann M, et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol April 2006, p. 295–305 https://doi.org/10.1038/nrmicro1384 PMID: 16541137

13. Roggenkamp A, Sing A, Horner M, Brunner U, Autenrieth IB, Heesemann J. Chronic Prosthetic Hip Infection Caused by a Small-Colony Variant of Escherichia coli. J Clin Microbiol Sept. 1998, p. 2530–4 https://doi.org/10.1128/JCM.36.9.2530-2534.1998 PMID: 9705387

14. Johns BE, Purdy KJ, Tucker NP, Maddocks SE. Phenotypic and Genotypic Characteristics of Small Colony Variants and Their Role in Chronic Infection. Microbiology Insights 2015: 8 15–23 https://doi.org/10.4137/MBI.S25800 PMID: 26448688

15. Kriegeskorte A, Loré NI, Bragonzi A, Riva C, Kelkemberg M, Becker K, et al. Thymidine-Dependent Staphylococcus aureus Small-Colony Variants Are Induced by Trimethoprim-Sulfamethoxazole (SXT) and Have Increased Fitness during SXT Challenge. Antimicrob Agents Chemoth. 2015; 59 (12):7265–72.

16. Besier S, Ludwig A, Ohlsen K, Brade V, Wichelhaus TA. Molecular analysis of the thymidine- auxotrophic small colony variant phenotype of Staphylococcus aureus. Int J Med Microbiol. 2007; 297:217–25. https://doi.org/10.1016/j.ijmm.2007.02.003 PMID: 17412637
17. Negishi T, Matsumoto T, Horiiuchi K, Kasuga E, Natori T, Matsuoka M et al. Characterization of clinically isolated thymidine-dependent small-colony variants of Escherichia coli producing extended spectrum β-lactamase. J Med Microbiol 2018; 67:33–9 https://doi.org/10.1099/jmm.0.000634 PMID: 29143727

18. Nagano N, Kawakami Y, Matsumoto T, Tanimoto K, Kashihara M, Nagata M. et al. Isolation of thymidine-dependent and extended-spectrum-beta-lactamase-producing Escherichia coli small-colony variant from urine of a septuagenarian female patient with recurrent cystitis: A case report with genetic investigation. J Infect Chem Oct 2020, Vol 26,Issue 10, p. 1066–9 https://doi.org/10.1016/j.jiac.2020.05.013 PMID: 32571646

19. Clinical breakpoints—bacteria v 5.0. The European Committee on Antimicrobial Susceptibility Testing, http://www.eucast.org/clinical_breakpoints.

20. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012; 19(5):455–77. https://doi.org/10.1089/cmb.2012.0021 PMID: 22506599

21. Seemann T. Abricate, Github https://github.com/tsseemann/abricate

22. National Database of Antibiotic Resistant Organisms (NDARO). National Center for Biotechnology Information, https://www.ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance

23. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MTG. Roary: rapid large-scale prokaryote pan genome analysis. Bioinformatics. 2015; 31(22): 3691–3 https://doi.org/10.1093/bioinformatics/btv421 PMID: 26198102

24. Price MN, Dehal PS, Arkin AP. FastTree 2:Approximately Maximum-Likelihood Trees for Large Alignments. Plos One. 2010; 5(3). https://doi.org/10.1371/journal.pone.0009490 PMID: 20224823

25. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. Mol. Biol. Evol. 2018; 35(6):1547–9 https://doi.org/10.1093/molbev/msy096 PMID: 29722887

26. Steward PS and Bjarnsholt T. Risk factors for chronic biofilm-related infection associated with implanted medical devices. Clin Microbiol Inf 2020; 26: 1034–8 https://doi.org/10.1016/j.cmi.2020.02.027 PMID: 32120041

27. Zapf JW, Weir MS, Emerick V, Villafranca JE, Dunlap RB. Substitution of glutamine for glutamic acid-58 in Escherichia coli thymidylate synthase results in pronounced decreases in catalytic activity and ligand binding. Biochemistry. 1993; 32(36):9274–81. https://doi.org/10.1021/bi00087a003 PMID: 8103678

28. Ahmad SI, Kirk SH, Eisenstark A. Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Annu Rev Microbiol. 1998; 52:591–625. https://doi.org/10.1146/annurev.micro.52.1.591 PMID: 9891809

29. Goldberg E, Bishara J. Contemporary unconventional clinical use of co-trimoxazole. Clin Microbiol Infect 2012; 18: 8–17 https://doi.org/10.1111/j.1469-0691.2011.03613.x PMID: 21851485

30. Al-Hasan MN, Rac H. Transition from intravenous to oral antimicrobial therapy in patients with uncomplicated and complicated bloodstream infections. Clin Microbiol Inf 2020; 26: 299–306 https://doi.org/10.1016/j.cmi.2019.05.012 PMID: 31128289